The PurpleLab^® Resource Center

Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

PurpleLab®, a leading health tech company specializing in real-world data and medical claims insights, and Payerset, the industry leader in enterprise price transparency data, announced today a strategic partnership to launch a trusted price intelligence solution suite, setting a new standard in healthcare intelligence.  This collaboration empowers healthcare organizations with unparalleled accuracy and actionable insights,…

Enhance clinical trial development with PurpleLab’s data-driven insights. ​ Access patient-level data, optimize trial design, improve recruitment, and generate real-world evidence.